A PYMNTS Company

Switzerland: Nestle pays $1.4B to boost skincare portfolio

By  |  May 28, 2014

Swiss food conglomerate Nestle is reportedly expanding its skincare portfolio after acquiring various injectable treatment patents in a $1.4 billion deal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say Nestle acquired the rights for various wrinkle treatments from Valeant Pharmaceuticals.

    While the deal allows Nestle to own the rights to treatments acquired when it fully took over its joint venture with Galderma, the transaction poses benefits for Valeant, as well. According to reports, the sale unloads a possible antitrust hurdle for Valeant, which is looking to acquire US Botox maker Allergan.

    Some analysts, however, doubt that the acquisition will be as beneficial to Nestle as intended. The company has been looking for years to expand from a confectionary company into a global healthcare and nutrition brand; some experts, reports say, doubt that winkle treatment fits under that market.

    Full content: International Business Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.